Oral glutamine ameliorates chemotherapy-induced changes of intestinal permeability and does not interfere with the antitumor effect of chemotherapy in patients with breast cancer: A prospective randomized trial

Tumori

Volumn 92, Issue 5, 2006, Pages 396-401

  Li, Yousheng ^a   Yu, Zeping ^a   Liu, Fangnan ^a   Tan, Li ^a   Wu, Bo ^a   Li, Jieshou ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Breast cancer; Chemotherapy; Glutamine; Intestinal permeability

Indexed keywords

CYCLINE; GLUTAMINE; KI 67 ANTIGEN; LACTOSE; MANNITOL; PLACEBO;

ADJUVANT CHEMOTHERAPY; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; ENTEROPATHY; FEMALE; HUMAN; INTESTINE MUCOSA PERMEABILITY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; VOMITING;

EID: 33845242540     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200505     Document Type: Article

References (32)

1. Parrilli G, Iaffaioli RV, Capuano G, Budillon G, Bianco AR: Changes in intestinal permeability to lactulose induced by cytotoxic chemotherapy. Cancer Treat Rep, 66: 1435-1436, 1982.
2. Daniele B, Perrone F, Gallo C, Pignata S, De Martino S, De Vivo R, Barletta E, Tambaro R, Abbiati R, D'Agostino L: Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut, 48: 28-33, 2001.
3. Sukkar SG, Schenone E, Foppiani L, Nobile MT: Experimental assessment of chemotherapy-induced early intestinal damage in colon cancer the lactulose-mannitol permeability test. Tumori, 90: 461-463, 2004.
4. Melichar B, Dvorak J, Hyspler R, Zadak Z: Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents. Chemotherapy, 51: 336-338, 2005.
5. Olaison G, Sjodahl R, Tagesson C: Abnormal intestinal permeability in Crohn's disease: A possible pathogenic factor. Scand J Gastroenterol, 125: 321-328, 1990.
6. De-Souza DA, Greene LJ: Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. Crit Care Med, 33: 1125-1135, 2005.
7. Li Y, Li J, Jiang J, Li N, Wang X, Wang Z, Wu B, Liu F: Glycyl-glutamine-supplemented long-term total parenteral nutrition selectively improves structure and function in heterotopic small-bowel autotransplantation in the pig. Transpl Int, 16: 866-871, 2003.
8. Siber GR, Mayer RJ, Levin MJ: Increased gastrointestinal absorption of large molecules in patients after 5-fluorouracil therapy for metastatic colon carcinoma. Cancer Res, 40: 3430-3436, 1980.
9. Parrilli G, Iaffaioli RV, Martorano M, Cuomo R, Tafuto S, Zampino MG, Budillon G, Bianco AR: Effects of anthracycline therapy on intestinal absorption in patients with advanced breast cancer. Cancer Res, 49: 3689-3691, 1989.
10. Lifschitz CH, Mahoney DH: Low-dose methotrexate-induced changes in intestinal permeability determined by polyethylene glycol polymers. J Pediatr Gastroenterol Nutr, 9: 301-306, 1989.
11. Selby PJ, Lopes N, Mundy J, Crofts M, Millar JL, McElwain TJ: Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy. Br J Cancer, 55: 531-533, 1987.
12. Ziegler TR, Bazargan N, Leader LM, Martindale RG: Glutamine and the gastrointestinal tract. Curr Opin Clin Nutr Metab Care, 3: 355-362, 2000.
13. Fox AD, Kripke SA, De Paula J, Berman JM, Settle RG, Rombeau JL: Effect of a glutamine-supplemented enteral diet on methotrexate enterocolitis. JPEN J Parenter Enteral Nutr, 12: 325-331, 1988.
14. Gardner ML, Earl SD, Wood D: Elemental diets in the repair of small intestinal damage. Nutrition, 13: 755-975, 1997.
15. Bozzetti F, Biganzoli L, Gavazzi C, Cappuzzo F, Carnaghi C, Buzzoni R, Di Bartolomeo M, Bajetta E: Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study. Nutrition, 13: 748-751, 1997.
16. Yoshida S, Kaibara A, Ishibashi N, Shirouzu K: Glutamine supplementation in cancer patients. Nutrition, 17: 766-768, 2001.
17. Anderson PM, Schroeder MS, Skubitz KM: Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer, 83: 1433-1439, 1998.
18. Liu FN, Li JS, Li YS, Sheng XQ, Chen YM: Plasma glutamine level monitored with high performance liquid chromatography for patients infusing glutamine after small bowel transplantation. China J Chromatogr, 15: 445-446, 1997.
19. Jiang XH, Li N, Liu FN: Measurement of intestinal permeability in healthy Chinese. Parenter Enteral Nutr, 8: 233-234, 2001.
20. Blijlevens NMA: Implications of treatment-induced mucosal barrier injury. Curr Opin Oncol, 17: 605-610, 2005.
21. Blijlevens NMA, van't Land B, Donnelly JP, M'Rabet L, de Pauw BE: Measuring mucosal damage induced by cytotoxic therapy. Support Care Cancer, 12: 227-233, 2004.
22. Daniele B, Secondulfo M, De Vivo R, Pignata S, De Magistris L, Delrio P, Palaia R, Barletta E, Tambaro R, Carratu R: Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer. J Clin Gastroenterol, 32: 228-230, 2001.
23. Fazeny-Dorner B, Veitl M, Wenzel C, Brodowicz T, Zielinski C, Muhm M, Vogelsang H, Marosi C: Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, adriamycin, dacarbazine). Cancer Chemother Pharmacol, 49: 294-298, 2002.
24. Welsh FKS, Ramsden CW, MacLennan K Sheridan MB, Barclay GR, Guillou PJ, Reynolds JV: Gut barrier function in malnourished patients. Gut, 42: 396-401, 1998.
25. Jebb SA, Osborne RJ, Maughan TS, Mohideen N, Mack P, Mort D, Shelley MD, Elia M: 5-fluorouracil and folinic acid induced mucositis: no effect of oral glutamine supplementation. Br J Cancer, 70: 732-725, 1994.
26. Okuno SH, Woodhouse CO, Loprinzi CL, Sloan JA, LaVasseur BI, Clemens-Schutjer D, Swan D, Axvig C, Ebbert LP, Tirona MR, Michalak JC, Pierson N: Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (S-FU)-based chemotherapy. Am J Clin Oncol, 22: 258-261, 1999.
27. Muscaritoli M, Micozzi A, Conversano L, Martino P, Petti MC, Cartoni C, Cascino A, Rossi-Fanelli F: Oral glutamine in the prevention of chemotherapy-induced gastrointestinal toxicity. Eur J Cancer, 33: 319-320, 1997.
28. Klimberg VS, McClellan JL: Claude H. Organ, Jr. Honorary Lectureship. Glutamine, cancer, and its therapy. Am J Surg, 172: 418-424, 1996.
29. Kang YJ, Feng Y, Hatcher EL: Glutathione stimulates A549 cell proliferation in glutamine-deficient culture: the effect of glutamate supplementation. J Cell Physiol, 161: 589-596, 1994.
30. Bartlett DL, Charland S, Torosian MH: Effect of glutamine on tumor and host growth. Ann Surg Oncol, 2: 71-76, 1995.
31. Chance WT, Cao L, Kim MW, Nelson JL, Fischer JE: Reduction of tumor growth following treatment with a glutamine antimetabolite. Life Sci, 42: 87-94, 1988.
32. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA, International Breast Cancer Study Group: Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors - a surrogate marker? Cancer, 97: 1321-1431, 2003.